الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 101 |  |  |
| | | from | 101 | | |
Abstract
AML is a heterogeneous group of diseases characterized by uncontrolled proliferation of myeloid progenitors in the bone marrow. Leukemic myeloid cells gradually replace normal hematopoiesis in bone marrow. The genetic changes arising in the neoplastic clone leads to cascades of molecular events that cause abnormal proliferation, aberration, differentiation, and inhibition of normal hematopoiesis by the malignant cells.
MicroRNAs (miRNAs) are short non-coding RNAs of ~ 21 to 23 nucleotides in length that post-transcriptionally regulate mRNA expression. High-throughput methodologies have shown deregulated miRNA expression in an increasing number of human cancers including colon, breast, lung, thyroid, cervical, ovarian and pancreatic cancers. MiRNA expression patterns have been found to distinguish tumors of different developmental origin, better even than traditional mRNA expression profiling.
miR-126 is located within intron 7 of the host gene, namely epidermal growth factor-like 7 (EGFL7) and its expression is associated with epigenetic regulation. Overexpression and knockout were found to restrain cell cycle progression, prevent differentiation, and increase self-renewal of primary LSCs.
The search for non-invasive tools for diagnosis and management of cancer is extremely important for reducing the worldwide health burden of cancer. MiRNAs show potential as biomarkers and can even be found circulating in the serum.
The aim of this study was to assess the expression of miR-126 in newly diagnosed AML and correlate it to other well-established prognostic factors in adult AML and to the remission status post induction chemotherapy.
This study was carried out on thirty nine subjects with acute myeloid leukemia admitted to hematology unit in Alexandria Main University Hospital as patients group as well as ten healthy subjects with matched age as control group.
Conventional cytogenetic were done to AML patients group while measurement of plasma level of miR-126 using TaqMan quantitative RT-PCR and RNU48 as standardization was done to both groups. All AML